Clinical Trial

Examining Lithium's Mechanism in Bipolar Disorder

Study acronym: HELIOS-BD 2
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The primary objective of the current study is to examine the acute effect of lithium on the visual and non-visual responses to light in a sample of healthy participants. Our experiments will investigate the effects of lithium on light sensitivity at the level of the retina as well as central visual and non-visual pathways. Our primary hypothesis is that the administration of lithium to healthy volunteers will reduce the magnitude of a range of non-visual responses to light including melatonin suppression, alertness, performance, mood and electrophysiology in a manner that is dependent of the amount of lithium in the brain. To better understand the postulated effects of lithium on light sensitivity and to examine its relationship at the level of the retina, we will assess the visual and non-visual responses to light, as well as the distribution of lithium in the brain using a non-invasive imaging technique. In addition to that, we also aim to examine the impact of both lithium and light on a molecular level through whole blood transcriptome sequencing.
Trial Details
NCT Number NCT07750925
Lead Sponsor Northumbria University
Collaborators: Newcastle University, Northumberland, Tyne and Wear NHS Foundation Trust
Conditions Healthy, Bipolar
Enrollment 45 participants
Start Date 2026-08-01
Primary Completion 2028-04-30 (estimated)
Study Completion 2029-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-06